Leadership Changes
The board appointed Steve Hoerter, who had served as Executive Chairman since November 2025 and joined the board in April 2025, as the new Chairman and Chief Executive Officer of MBX Biosciences Inc, effective immediately. Hoerter replaces Kent Hawryluk, who resigned from his positions as President, Chief Executive Officer, and board member. John Smither, who had been serving as Interim Chief Financial Officer since March 2026, was confirmed as the permanent Chief Financial Officer. Smither brings more than 25 years of biopharmaceutical finance experience, previously holding CFO roles at Arcutis Biotherapeutics—where he led the IPO and four follow‑on financings—as well as at Sienna Biopharmaceutics, UNITY Biotechnology, and Kythera Biopharmaceuticals.
Stock Reaction
Following the leadership announcement, MBX Biosciences shares fell 8.3% in after‑hours trading on Monday, as reported on 14 July 2026.
Operational Milestones
The company reiterated that it remains on track to achieve three key milestones in the second half of 2026: (i) initiation of the Phase 3 clinical trial of canvuparatide for chronic hypoparathyroidism; (ii) nomination of a GLP‑1/GIP/GCGR triple‑agonist candidate for obesity treatment; and (iii) release of 12‑week multiple ascending dose (MAD) data for its pipeline asset MBX 4291.
Company Focus
MBX Biosciences continues to develop precision peptide therapies targeting endocrine and metabolic disorders, leveraging its proprietary PEP platform.